spacer
home > ebr > spring 2018 > data swap
PUBLICATIONS
European Biopharmaceutical Review

Data Swap

Biobanks play a significant role in the drug discovery process by providing researchers access to unique sample sets that can be linked to identifying characteristics, which, in turn, can accurately diagnose disease and predict drug response.

Today’s research biobank typically provides physical sample storage and maintains associated data within their databases. Information about acquisition, quality, state, location, processing outcomes, quantity, and usage are all generally available at a minimum, but are primarily focused on the sample characteristics. However, researchers want to link individualities to attributes of the donor, including phenotypical, demographical, genetic, or lifestyle attributes.

A challenge can present itself between the biobank resources and requirements of the research community. The types and amount of data linked to the physical sample that is needed to identify pertinent information can grow more important and complex. Therefore, meeting the expanding specificity of research programmes requires each sample within a biorepository to be connected to as comprehensive a data array as possible to deliver maximum value.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Thurston is Director of Informatics at Brooks Life Sciences, having joined the company in 2015. He has worked in the field of laboratory informatics for over 20 years and has experience in the development, sales, support and marketing of a variety of laboratory software. A graduate of Salford University, UK, with a BSc in chemistry, Colin began his career researching solid-state secondary lithium batteries.
spacer
Colin Thurston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement